Disease Domain | Count |
---|---|
Neoplasms | 5 |
Immune System Diseases | 2 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Chemical drugs | 2 |
Monoclonal antibody | 1 |
Target |
Mechanism SIRT3 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AHR agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NF-κB inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GDU-952 ( AHR ) | Dermatitis, Atopic More | Preclinical |
SIRT3 agonists(Guangdong University of Technology) ( SIRT3 ) | Cardiovascular Diseases More | Preclinical |
Carboxymethylated Poria Cocos Polysaccharides ( NF-κB x Nrf2 ) | Acute kidney injury due to sepsis More | Preclinical |
CN116621963 ( IGFBP1 )Patent Mining | Neoplasms More | Discovery |
CN119925473 Patent Mining | Inflammation More | Discovery |